Education and Training:

B.S., University of Kansas, Lawrence, KS (1978)

M.D., University of Kansas, Kansas City, KS (1982)

Internship/Residency, Department of Medicine, Rhode Island Hospital, Providence, RI (1982-85)

Fellowship, Department of Medicine, Division of Hematology, University of Washington, Seattle, WA (1986-89)

Michael L. Linenberger, M.D., F.A.C.P.
Professor of Medicine, Division of Hematology
Robert and Phyllis Henigson Professorship in Hematology
Program Director, Hematology/Oncology Fellowship Program
University of Washington School of Medicine

Medical Director, Apheresis and Cellular Therapy,
Seattle Cancer Care Alliance
Associate Member,
Fred Hutchinson Cancer Research Center

CURRENT CLINICAL INTERESTS

Hematologic malignancies, benign hematologic disorders, bleeding and thrombotic disorders, therapeutic apheresis and stem cell procurement

CURRENT RESEARCH INTERESTS

Safe and effective management of patients and donors undergoing marrow harvest and peripheral blood stem cell mobilization and collection by apheresis

RESEARCH DESCRIPTION

Dr. Linenberger is the local principal investigator on a multicenter study of hematopoietic stem cell donor safety and quality of life, sponsored by the Center for International Blood and Marrow Transplant Research.  In his role as Medical Director of Cellular Therapy and Apheresis, Dr. Linenberger supports the activities of the Cell Processing Core of the Fred Hutchinson Cancer Research Center (FHCRC), which provides critical instrumentation and technical expertise for the procurement, characterization and processing of all clinical cellular components necessary for the treatment of patients and for correlative research studies. These activities support the investigational protocols that utilize the Cellular Processing Facility (a GMP production laboratory) and a research specimen repository.

SELECTED PUBLICATIONS

Linenberger ML, Kindelan J, Bennett RL, Reiner AP, and Côté HCF:  Fibrinogen Bellingham: A g-chain R275C substitution and a b-promoter polymorphism in a thrombotic member of an asymptomatic family.  Am. J. Hematol. 64:242-250, 2000.

Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, and Bernstein ID:  Multidrug resistance phenotype and clinical responses to gemtuzumab ozogamicin.  Blood 98:988-994, 2001.

Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, and Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.  Blood 102:1466-1473, 2003.

Linenberger ML and Wittkowski AK.  Thromboembolic complications of malignancy: Part 1.  Risks.  Oncology 19: 853-861, 2005.

Linenberger ML. CD33-Directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of resistance. Leukemia 19:176-182, 2005.

Linenberger ML and Wittkowski AK.  Thromboembolic complications of malignancy: Part 2.  Management.  Oncology 19:1077-1084, 2005.

Linenberger M: Catheter-related thrombosis: risks, diagnosis and management. J. Natl. Compr. Canc. Netw. 4:889-901, 2006.

Shaz BH, Linenberger ML, Bandarenko N et al. Category IV indications for therapeutic apheresis-ASFA fourth special issue. J. Clin. Apheresis 22:176-180, 2007.

Hsia CC, Linenberger M, Howson-Jan K, et al.  Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF. Leukemia 42:431-2, 2008.

Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, Lee J, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB, Vedantham S; National Comprehensive Cancer Network. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 6:716-53, 2008.

Valji K and Linenberger M, Chasing clot: thrombophilic states and the interventionist. J. Vasc. Interv. Radiol. 20:1403-16 2009.

Linenberger M: Collection of cellular therapy products by apheresis.  In Cellular Therapy: Principles, Methods and Regulations, Ellen M Areman and Kathy Loper (eds), AABB Press, 2009.

Szczepiorkowski ZM*, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Apheresis 25:83-177, 2010.

Schwartz J, Padmanabhan A, Francis R and Linenberger M: Mobilization and collection of peripheral blood hematopoietic progenitor cells.  In Apheresis: Principles and Practice, 3^rd Edition, McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL (eds), Bethesda, MD:  AABB Press, 2010.

Nester T and Linenberger, M: Therapeutic apheresis: Technical considerations and indications in critical care. In Irwin and Rippe’s Intensive Care Medicine 7^th Edition, Richard S. Irwin and James M. Rippe (eds), Wolters Kluwer/Lippincott Williams & Wilkins, 2012.

Khera N, Jinneman J, Storer BE, Heimfeld S, O'Meara MM, Chauncey TR, Lee SJ, Linenberger M. Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic Engraftment. Biol Blood Marrow Transplant 18:220-28, 2012.

Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, Sandmaier BM, Myerson D, Chauncey TR, Storb R, Buxhofer-Ausch V, Radich JP, Appelbaum FR, Deeg HJ. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 119:2657-64, 2012.

Gopal AK, Karami M, Mayor J, Macebeo M, Linenberger M, Bensinger WI, Holmberg L.  The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34+ cells. J Clin Apheresis 27:81-7, 2012.